Heart failure & cardiomyopathies
Myeloperoxidase Inhibition Reverses Biomarker Profiles Associated With Clinical Outcomes in Heart Failure with Preserved Ejection Fraction (HFpEF)
Authors' conclusion
Biomarker pathways that were most strongly associated with clinical outcomes were also the ones reduced by AZD4831.
Study context
- Population
- Patients with HFpEFcohorts n = 86, 216, 242
- Comparison
- Biomarker profiles associated with outcomes in observational HFpEF cohorts vs profiles of AZD4831 vs placebo in SATELLITE
- Outcome
- Biomarkers and pathways associated with clinical outcomes in HFpEF cohorts, and their change with AZD4831 vs placebo
Methodological detailssupervised principal component analyses, 3 independent observational cohorts, double-blind randomized 3-month trial (SATELLITE)
- Supervised principal component analyses
- 3 independent observational cohorts
- Double-blind randomized 3-month trial (SATELLITE)
Main finding
As reported in the abstract
- Top biomarkers associated with HF hospitalization or death: TNF-R1, TRAIL-R2, GDF15, U-PAR, ADM
- Biomarkers associated with lower functional capacity and poorer quality of life: FABP4, HGF, RARRES2, CSTB, FGF23
- AZD4831 downregulated many markers (most significantly CDCP1, PRELP, CX3CL1, LIFR, VSIG2)
- Top outcome-associated pathways (tumor microenvironments, wound healing signaling, cardiac hypertrophy signaling) predicted to be downregulated with AZD4831 vs placebo
Original publication
Myeloperoxidase Inhibition Reverses Biomarker Profiles Associated With Clinical Outcomes in HFpEF. JACC Heart Fail. Published 3 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →